Glaxosmithkline

2 records, newest first. Each line links to the FDA page it came from.

Refusal charges, in plain English

• LACKS N/C1 refused line

  Net quantity statement missing

  The packaged food appeared not to carry an accurate statement of the quantity of contents, such as net weight, measure, or count, on its label.

• NUTRIT LBL1 refused line

  Nutrition information missing from label

  The label or labeling appeared not to carry the nutrition information that U.S. law requires for the food.

• UNAPPROVED1 refused line

  Unapproved new drug

  The product appeared to be a new drug within the meaning of section 201(p) of the FD&C Act without an approved New Drug Application. FDA can apply this charge to a food or supplement whose labeling presents it for drug uses.

Questions about Glaxosmithkline

Is Glaxosmithkline on an FDA import alert?

No listing for Glaxosmithkline appears in the FDA import alerts SupplierRadar checked on October 26, 2026. Country-wide alerts may still apply to its products; see the United Kingdom page.

Has FDA refused shipments from Glaxosmithkline?

Yes. FDA refused 2 shipment lines from Glaxosmithkline between October 5, 2016 and October 2, 2024. The most recent, on October 2, 2024, was vitamin b12 (cyanocobalamin), charged as UNAPPROVED (unapproved new drug).

Why did FDA refuse Glaxosmithkline's shipments?

The most frequent charges are LACKS N/C (net quantity statement missing, 1 line) and NUTRIT LBL (nutrition information missing from label, 1 line).

What is Glaxosmithkline's FEI number?

Glaxosmithkline's FDA Establishment Identifier (FEI) is 3003451948.